| Budget Amount *help |
¥3,960,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥360,000)
Fiscal Year 2007: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2006: ¥2,400,000 (Direct Cost: ¥2,400,000)
|
|---|
| Research Abstract |
We have found that the glycosphingolipid molecular species from marine echinoderms possess anti-osteoporosis effects toward the osteoporosis model mice (OVX mice) by osteoclast colony assay and osteogenetic cell colony assay. Continuing our research for anti-osteoporosis compounds from echinoderms, we accomplished the following studies in these years.
The echinoderms used as materials were as follows. The starfish Linckia laevigata (collected at Okinawa) and Certonardoa semiregularis (collected at Fukuoka), sea cucumber Bohadschia argus, Thelenota ananas (each collected at Okinawa), and Stichopus japonicus (collected at the Inland Sea), and feather star Comanthina schlegeli (collected at Okinawa). These animals were extracted with CHC13/MeOH and the extracts were partitioned between water and organic solvent, and each fractions were purified by normal phase and reversed phase column chromatography. On the basis of chemical and spectroscopic evidences, we determined a new ganglioside molecular species from L. laevigata, a new ganglioside molecular species from S. japonicus, two new inositol-phosphoceramide type ganglioside molecular species from C. schlegeli, three glucocerebroside molecular species from T. ananas, two glucocerebroside molecular species from C. semiregularis and a galactocerebroside molecular species from B. argus. Galactocerebroside molecular species were further separated by reversed phase HPLC in a difference of the length of alkyl chain, to give the individual components of molecular species.
These sphingolipids obtained in this research are very useful for examination of structure activity relationship of the sphingolipid that the effectiveness was seen toward the OVX mice.
|
